Klin Farmakol Farm. 2015;29(2):49-52

Development of resistance of invasive bacteria related to antibiotic consumption

Milan Kolář1, Pavlína Štrbová2
1 Ústav mikrobiologie LF UP a FN Olomouc
2 Ústav klinické farmakologie LF UP a FN Olomouc

Increasing resistance of bacterial pathogens to antibiotic therapy represents a serious health problem. It is apparent that an integral part

of the sources of rational antibiotic therapy is surveillance of bacterial resistance. The present study aimed at analyzing the resistance

of invasive bacterial pathogens isolated from blood cultures with respect to consumption of antimicrobial agents. The obtained results

suggest a worrying situation concerning the resistance of certain invasive bacteria to antimicrobial drugs. Despite reduced consumption

of third-generation cephalosporins and fluoroquinolones, the resistance of Klebsiella pneumoniae to these antibiotics continues to rise.

A direct association between increased consumption and bacterial resistance was noted in piperacillin/tazobactam and carbapenems.

In the following period, surveillance of bacterial resistance and adherence to the principles of rational antibiotic therapy are necessary

to slow down the pace of this negative trend.

Keywords: bacteria, blood cultures, resistance, antibiotics

Published: July 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolář M, Štrbová P. Development of resistance of invasive bacteria related to antibiotic consumption. Klin Farmakol Farm. 2015;29(2):49-52.
Download citation

References

  1. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-685. Go to original source... Go to PubMed...
  2. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-ß-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51: 1987-1994. Go to original source... Go to PubMed...
  3. Hanulík V, Uvízl R, Husičková V, Htoutou Sedláková M, Kolář M. Bakteriální původci pneumonií u pacientů v intenzivní péči. Klin Mikrobiol Inf Lék 2011; 17: 134-139.
  4. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994; 150: 1545-1549. Go to original source... Go to PubMed...
  5. Kolář M, Htoutou Sedláková M, Šenkyříková M, Hanulík V, Honig P. Vliv rezistence Pseudomonas aeruginosa na antibioterapii. Klin Farmakol Farm 2013; 27: 101-105.
  6. European Antimicrobial Resistance Surveillance Network (EARS-Net). http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx.
  7. Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents 2001; 17: 357-363. Go to original source... Go to PubMed...
  8. Urbánek K, Kolář M, Lovečková Y, Strojil J, Šantavá L. Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains. J Clin Pharm Therapeutics 2007; 32: 403-408. Go to original source... Go to PubMed...
  9. Haller P, Tschudin S, Dangel M. Increase of resistant Enterobacter isolates and correlation with antibiotic consumption at the ward level. Poster presented in 16. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, 2006. http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=17620&XNSPRACHE_ID=2&XNKONGRESS_ID=26&XNMASKEN_ID=900.
  10. Htoutou Sedláková M, Vojtová V, Hanulík V, Suchánková H, Kolář M. Rezistence enterobakterií k vybraným antibiotikům v souvislosti s jejich spotřebou. Klin Farmakol Farm 2012; 26: 61-66.
  11. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. http://www.eucast.org/clinical_breakpoints.
  12. Anatomical therapeutic chemical (ATC) index (including defined daily doses (DDDs) for plain substances) Oslo: WHO collaboration centre for drug statistics methodology, 1996.
  13. Global Risks 2013, Eighth Edition. World Economic Forum, http://www3.weforum.org/docs/WEF_GlobalRisks_Report_2013.pdf.
  14. Kolář M, Urbánek K, Hanulík V, Vojtová V. Vliv antibiotické léčby na vývoj bakteriální rezistence. Klin Farmakol Farm 2010; 24: 181-183.




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.